LR12-peptide quantitation in whole blood by RP-HPLC and intrinsic fluorescence detection: Validation and

M Parent1, A Boudier1, P Maincent1

  • 1CITHEFOR, Université de Lorraine, EA 3452, Nancy, France.

Insights

A new HPLC method accurately quantifies the dodecapeptide LR12 in rat blood. This validated method aids in understanding peptide pharmacokinetics and degradation products.

Area of Science:

  • Analytical Chemistry
  • Pharmacology
  • Biochemistry

Background:

  • Accurate quantification of pharmaceutical peptides in biological matrices is crucial for pharmacokinetic studies.
  • The dodecapeptide LR12, an inhibitor of Triggering Receptor Expressed on Myeloid cells-1, requires a validated analytical method for blood analysis.
  • Existing methods may lack the sensitivity, selectivity, or robustness needed for complex biological samples like whole blood.

Purpose of the Study:

  • To develop and validate a simple, sensitive, selective, and robust High-Performance Liquid Chromatography (HPLC) method for quantifying the dodecapeptide LR12 in rat whole blood.
  • To optimize sample preparation techniques including protein precipitation and solid-phase extraction for efficient LR12 recovery.
  • To evaluate the pharmacokinetic profile of LR12 and its disulfide dimer in rats following intraperitoneal administration.

Main Methods:

  • Development of an HPLC method utilizing intrinsic fluorescence detection for LR12 quantitation.
  • Optimization of chromatographic separation using a core-shell C18 column in gradient mode with specific mobile phases.
  • Validation of the analytical method according to US Food and Drug Administration guidelines for bioanalytical methods.
  • Application of the validated method in a preliminary pharmacokinetic study in rats.

Main Results:

  • A validated HPLC method with a lower limit of quantitation of 50 ng/mL and linearity within the 50-500 ng/mL range was established.
  • Optimized protein precipitation and solid-phase extraction procedures enhanced sample cleanup and analyte recovery.
  • The method successfully differentiated between LR12 monomer and its disulfide dimer, identifying the dimer as a primary degradation product.
  • Preliminary pharmacokinetic data for LR12 and its dimer were obtained.

Conclusions:

  • This study presents the first fully validated HPLC method for the analysis of LR12 in rat blood samples.
  • The optimized pre-analytical steps offer a valuable framework for developing similar methods for other peptide-based therapeutics.
  • The developed method enables comprehensive pharmacokinetic and degradation product analysis of LR12.

Related Concept Videos